Results 61 to 70 of about 118,382 (307)
Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice. [PDF]
PLoS ONE, 2014 Neuropeptide FF (NPFF) is known to be an endogenous opioid-modulating peptide. Nevertheless, very few researches focused on the interaction between NPFF and endogenous opioid peptides. In the present study, we have investigated the effects of NPFF system
Zi-long Wang +10 more
doaj +1 more source
Scalable Production of Highly-Sensitive Nanosensors Based on Graphene Functionalized with a Designed G Protein-Coupled Receptor [PDF]
, 2014 We have developed a novel, all-electronic biosensor for opioids that consists of an engineered mu opioid receptor protein, with high binding affinity for opioids, chemically bonded to a graphene field-effect transistor to read out ligand binding.
Crook, Alexander +10 more
core +4 more sources
Impact of Positive Lifestyle Behaviors on Direct Health Care Cost Savings for Low Back Pain
Arthritis Care &Research, EarlyView.Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and health care cost savings related to low back pain (LBP). Methods This longitudinal study used data from the Australian Twin Back (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline. Physical activity
Ye Tian +8 more
wiley +1 more source
Visualizing endogenous opioid receptors in living neurons using ligand-directed chemistry
eLife, 2019 Identifying neurons that have functional opioid receptors is fundamental for the understanding of the cellular, synaptic and systems actions of opioids. Current techniques are limited to post hoc analyses of fixed tissues. Here we developed a fluorescent
Seksiri Arttamangkul +8 more
doaj +1 more source
Arthritis Care &Research, Accepted Article.Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner +9 more
wiley +1 more source
Divergent modulation of nociception by glutamatergic and GABAergic neuronal subpopulations in the periaqueductal gray [PDF]
, 2017 The ventrolateral periaqueductal gray (vlPAG) constitutes a major descending pain modulatory system and is a crucial site for opioid-induced analgesia. A number of previous studies have demonstrated that glutamate and GABA play critical opposing roles in
Bruchas, Michael R +7 more
core +2 more sources
Sex differences in medication discontinuation in axial spondyloarthritis.
Arthritis Care &Research, Accepted Article.Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall +9 more
wiley +1 more source
Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals
Advanced Functional Materials, EarlyView.This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee +4 more
wiley +1 more source
Frontiers in Pharmacology, 2014 Opioids are intensely addictive, and cessation of their chronic use is associated with a highly aversive withdrawal syndrome. A cellular hallmark of withdrawal is an opioid sensitive protein kinase A-dependent increase in GABA transporter-1 (GAT-1 ...
Elena Elizabeth Bagley
doaj +1 more source
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]
, 2015 RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano +33 more
core +1 more source